285 related articles for article (PubMed ID: 21830012)
1. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.
Bayraktar S; Gutierrez-Barrera AM; Liu D; Tasbas T; Akar U; Litton JK; Lin E; Albarracin CT; Meric-Bernstam F; Gonzalez-Angulo AM; Hortobagyi GN; Arun BK
Breast Cancer Res Treat; 2011 Nov; 130(1):145-53. PubMed ID: 21830012
[TBL] [Abstract][Full Text] [Related]
2. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
Copson ER; Maishman TC; Tapper WJ; Cutress RI; Greville-Heygate S; Altman DG; Eccles B; Gerty S; Durcan LT; Jones L; Evans DG; Thompson AM; Pharoah P; Easton DF; Dunning AM; Hanby A; Lakhani S; Eeles R; Gilbert FJ; Hamed H; Hodgson S; Simmonds P; Stanton L; Eccles DM
Lancet Oncol; 2018 Feb; 19(2):169-180. PubMed ID: 29337092
[TBL] [Abstract][Full Text] [Related]
3. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.
Arun B; Bayraktar S; Liu DD; Gutierrez Barrera AM; Atchley D; Pusztai L; Litton JK; Valero V; Meric-Bernstam F; Hortobagyi GN; Albarracin C
J Clin Oncol; 2011 Oct; 29(28):3739-46. PubMed ID: 21900106
[TBL] [Abstract][Full Text] [Related]
4. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.
Gonzalez-Angulo AM; Timms KM; Liu S; Chen H; Litton JK; Potter J; Lanchbury JS; Stemke-Hale K; Hennessy BT; Arun BK; Hortobagyi GN; Do KA; Mills GB; Meric-Bernstam F
Clin Cancer Res; 2011 Mar; 17(5):1082-9. PubMed ID: 21233401
[TBL] [Abstract][Full Text] [Related]
5. Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
Wang YA; Jian JW; Hung CF; Peng HP; Yang CF; Cheng HS; Yang AS
BMC Cancer; 2018 Mar; 18(1):315. PubMed ID: 29566657
[TBL] [Abstract][Full Text] [Related]
6. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations.
Bayraktar S; Gutierrez-Barrera AM; Lin H; Elsayegh N; Tasbas T; Litton JK; Ibrahim NK; Morrow PK; Green M; Valero V; Booser DJ; Hortobagyi GN; Arun BK
Clin Exp Metastasis; 2013 Jun; 30(5):631-42. PubMed ID: 23370825
[TBL] [Abstract][Full Text] [Related]
7. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
8. Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer.
Yadav S; Ladkany R; Yadav D; Alhalabi O; Khaddam S; Isaac D; Cardenas PY; Zakalik D
Clin Breast Cancer; 2018 Oct; 18(5):e1229-e1235. PubMed ID: 29402697
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea.
Ryu JM; Choi HJ; Kim I; Nam SJ; Kim SW; Yu J; Lee SK; Choi DH; Park YH; Kim JW; Seo JS; Park JH; Lee JE; Kim SW;
Breast Cancer Res Treat; 2019 Jan; 173(2):385-395. PubMed ID: 30350268
[TBL] [Abstract][Full Text] [Related]
10. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
Baretta Z; Mocellin S; Goldin E; Olopade OI; Huo D
Medicine (Baltimore); 2016 Oct; 95(40):e4975. PubMed ID: 27749552
[TBL] [Abstract][Full Text] [Related]
11. The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy.
Pearson EJ; Nair A; Daoud Y; Blum JL
Breast Cancer Res Treat; 2017 Feb; 162(1):59-67. PubMed ID: 28066861
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
Bignon L; Fricker JP; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Caron O; Lortholary A; Faivre L; Lasset C; Mari V; Gesta P; Gladieff L; Hamimi A; Petit T; Velten M
Breast J; 2018 May; 24(3):269-277. PubMed ID: 28929593
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
Rennert G; Bisland-Naggan S; Barnett-Griness O; Bar-Joseph N; Zhang S; Rennert HS; Narod SA
N Engl J Med; 2007 Jul; 357(2):115-23. PubMed ID: 17625123
[TBL] [Abstract][Full Text] [Related]
14. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
Hyman DM; Zhou Q; Iasonos A; Grisham RN; Arnold AG; Phillips MF; Bhatia J; Levine DA; Aghajanian C; Offit K; Barakat RR; Spriggs DR; Kauff ND
Cancer; 2012 Aug; 118(15):3703-9. PubMed ID: 22139894
[TBL] [Abstract][Full Text] [Related]
15. Genomic Profiling Comparison of Germline
Huang X; Shao D; Wu H; Zhu C; Guo D; Zhou Y; Chen C; Lin Y; Lu T; Zhao B; Wang C; Sun Q
Front Oncol; 2020; 10():583314. PubMed ID: 33194720
[No Abstract] [Full Text] [Related]
16. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
Zhang J; Yao L; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2021 Feb; 148(4):941-949. PubMed ID: 32720318
[TBL] [Abstract][Full Text] [Related]
17. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis.
Zhu Y; Wu J; Zhang C; Sun S; Zhang J; Liu W; Huang J; Zhang Z
Oncotarget; 2016 Oct; 7(43):70113-70127. PubMed ID: 27659521
[TBL] [Abstract][Full Text] [Related]
18. Clinical and pathologic differences between BRCA1-, BRCA2-, and non-BRCA-associated breast cancers in a multiracial developing country.
Yip CH; Taib NA; Choo WY; Rampal S; Thong MK; Teo SH
World J Surg; 2009 Oct; 33(10):2077-81. PubMed ID: 19649760
[TBL] [Abstract][Full Text] [Related]
19. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
Atchley DP; Albarracin CT; Lopez A; Valero V; Amos CI; Gonzalez-Angulo AM; Hortobagyi GN; Arun BK
J Clin Oncol; 2008 Sep; 26(26):4282-8. PubMed ID: 18779615
[TBL] [Abstract][Full Text] [Related]
20. Influence of germline
Villarreal-Garza C; Ferrigno AS; Aranda-Gutierrez A; Frankel PH; Ruel NH; Fonseca A; Narod S; Chavarri-Guerra Y; Sifuentes E; Magallanes-Hoyos MC; Herzog J; Castillo D; Alvarez-Gomez RM; Mohar-Betancourt A; Weitzel JN
Cancer Res Commun; 2021 Dec; 1(3):140-147. PubMed ID: 35875314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]